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intravenous administration of its liver-targeted dextran prodrug
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Quentin R. Smith, and Reza Mehvar*
Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health
Sciences Center, 1300 Coulter, Amarillo, TX 79106, USA
Abstract
A specific and sensitive liquid chromatography (LC)-tandem mass spectrometric method for
quantitative determination of methylprednisolone (MP) in rat plasma and liver was developed and
validated using triamcinolone acetonide as an internal standard. Liquid-liquid extraction using tert-
butyl methyl ether was used to extract the drug and the internal standard from plasma and liver. The
separation of MP was performed on a C18 column with a mobile phase of acetonitrile:0.5% formic
acid aqueous solution (85:15, v/v) over 4 min. The assay was based on the selected reaction
monitoring transitions at m/z 375→161 for MP in plasma, 375→357 for MP in liver, and 435→415
for internal standard in both plasma and liver. The lower limit of quantification was 20 ng/mL based
on 100 μL of plasma or liver homogenate. Intra- and inter-day assay variations were ≤15%, and the
accuracy values were between 85.8 and 118%. The extraction recoveries ranged from 76.8 to 79.2%
for plasma and 76.8 to 80.8% for liver across the calibration curve range. The method was
successfully applied to measurement of low concentrations of regenerated MP in plasma and liver
after intravenous administration of a single dose (5 mg/kg) of a liver-targeted dextran prodrug of MP
to rats.
Keywords
Methylprednisolone; Dextran-methylprednisolone prodrug; Rat plasma; Rat liver; Liquid
chromatography-tandem mass spectrometry; Pharmacokinetics
1. Introduction
Methylprednisolone (MP) is a glucocorticoid with well-defined anti-inflammatory and
immunosuppressive effects, which has been widely used for prevention of graft rejection in
organ transplantation [1,2]. However, the use of steroids and other immunosuppressants in
organ transplantation has been associated with significant toxicity, such as diabetes,
hypertension, Cushing syndrome, and osteoporosis [3–5]. Recently, we synthesized a
macromolecular prodrug of MP using dextran as a carrier and succinic acid as a linker, and
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investigated its hydrolysis kinetics [6], pharmacokinetics [7], and pharmacodynamics [8,9] in
rats. It was demonstrated that the prodrug would selectively accumulate and gradually release
MP in the liver and spleen, resulting in a more intense and sustained immunosuppressive
activity in these organs, compared to administration of an equal dose of the parent drug. Further
studies [10] in a rat transplantation model showed that this dextran prodrug of MP is more
effective than the parent drug in preventing rejection of the liver allograft. However, despite
very high accumulation of the conjugate in the liver and spleen, the release of MP from the
conjugate was slow and incomplete [6,9]. Therefore, the second generation dextran-MP (DMP)
prodrugs with various peptides as linkers were synthesized and investigated in the presence of
various peptidases, rat liver lysosomes, and buffers with different pH values [11]. These newly
developed dextran conjugates of MP with peptide linkers exhibited promise for controlled
delivery of MP in liver lysosomes. However, further pharmacokinetic studies in animals are
needed to test the selective delivery of MP to the liver and the regeneration kinetics of MP after
systemic administration of dextran-peptide-MP conjugates.
A prerequisite for pharmacokinetic studies involving regeneration of MP from its
macromolecular prodrugs is a sensitive assay capable of measurements of low concentrations
of MP in small volumes of biological samples in animals such as rodents. Very recently [12],
LC coupled with tandem mass spectrometry (LC-MS/MS) was used to estimate the
concentrations of a number of immunosuppressants, including MP, after solid-phase extraction
of the analytes from 0.5 mL of human plasma. Additionally, other LC-MS/MS assays have
been reported for the measurement of MP in urine [13,14]. However, to date, no literature on
the determination of MP in rat plasma (≤ 100 μL) and/or the liver tissue using LC-MS or LC-
MS/MS is available. Therefore, the purpose of this study was to develop a novel LC-MS/MS
method for the measurement of regenerated MP in small volumes of rat plasma and liver. The
assay was successfully applied to determination of the in vitro stability of DMP in biological
samples and to a pharmacokinetic study in rats after intravenous administration of the prodrug
DMP or the parent drug MP at a single MP-equivalent dose of 5 mg/kg.
2. Experimental
2.1. Materials
Dextran with an average molecular weight of 23,500 was obtained from Dextran Products Ltd.
(Scarborough, Ontario, Canada). MP and MP succinate were purchased from Steraloids
(Newport, RI, USA). Triamcinolone acetonide, as an internal standard (IS), was obtained from
Sigma (St. Louis, MO, USA). HPLC grade acetonitrile was from VWR Scientific
(Minneapolis, MN, USA). Tert-butyl methyl ether (TBME) was obtained from Fisher (Fair
Lawn, NJ, USA). Rat plasma was purchased from Lampire Biological Laboratories
(Pipersville, PA, USA). All other reagents were analytical grade and obtained through
commercial sources.
2.2. Synthesis of DMP
DMP conjugate with a peptide linker consisting of methyl Gly-Gly-Gly-Gly-Gly (Fig. 1) was
synthesized from dextran 23,500 and MP succinate as described before [11]. The degree of
substitution of MP and the purity of the conjugate were also examined as explained before
[11].
2.3. LC-MS/MS instrumentation
LC-MS/MS system was from Varian (Palo Alto, CA, USA) and consisted of a ProStar 430
autosampler, two ProStar 210 pumps, and a 1200 L triple quadrupole mass spectrometer
equipped with an electrospray ionization source. Varian MS workstation version 6.8 software
was used for data acquisition and processing.
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2.4. Liquid chromatographic conditions
The chromatographic separation was performed on a Pursuit C18 column (150 mm × 2.0 mm,
5 μm particle size, Varian Inc., Lake Forest, CA, USA) at ambient temperature. The same
packing material (MetaGuard guard cartridge, 4 mm×2.0 mm, Varian Inc., Lake Forest, CA,
USA) was used to extend the life of the analytical column. The mobile phase consisted of
acetonitrile: 0.5% (v/v) formic acid aqueous solution (85:15, v/v) operated at a flow rate of 0.2
mL/min. The injection volume was 10 μL, and the analysis time was 4 min per sample.
2.5. Mass spectrometer conditions
The ESI-MS spectrometer was operated in the positive ion mode. The electrospray capillary
voltage was set to 60 V. Nitrogen was used as a drying gas for solvent evaporation. The API
housing and drying gas temperatures were kept at 50 and 275 °C, respectively. Protonated
analyte molecules were subjected to collision induced dissociation using argon as the collision
gas to yield product ions for MP and IS. The scan time was 0.8 s and the detector multiplier
voltage was set to 1100 V. Selected reaction monitoring (SRM) of the precursor–product ion
transitions m/z 375→161 for MP in plasma, 375→357 for MP in liver, and 435→415 for IS
in plasma and liver was used for quantification. The collision energy was 18 and 7.5 eV for
MP at 375→161 and 375→357, respectively, and 5.5 eV for IS.
2.6. Standard and working solutions
Individual stock solutions of MP (1 mg/mL) and IS (5 μg/mL) were prepared by accurately
weighing the required amounts into separate volumetric flasks and dissolving in acetonitrile.
The calibration standard for MP was prepared by spiking 4.95 mL of blank rat plasma with 50
μL of MP stock solution. The resulting plasma standard had a concentration of 10,000 ng/mL.
Further dilutions were made from this stock with blank plasma to afford plasma standards in
the range of 20–5000 ng/mL. For preparation of liver standards, blank livers were collected
from male Sprague-Dawley rats that had not received any drug treatment. Subsequently, the
blank liver tissue was homogenized in three volumes of 2% (v/v) acetic acid solution using a
tissue homogenizer (Biospec Products, Bartlesville, OK, USA) at a speed of 10,000 rpm for 2
min. Similar to plasma standards, the liver homogenate standards were prepared by first adding
50 μL of MP stock solution to 4.95 mL of the homogenate. Liver homogenate standards in the
range of 20–1000 ng/mL were then prepared by diluting this homogenate with blank
homogenate.
2.7. Sample preparation
To 100 μL of plasma or liver homogenate sample was added 10 μL of IS solution. Following
the addition of 1.5 mL of TBME, the sample was vortex-mixed for 10 min and then centrifuged
at 10,000 rpm for 5 min. The resultant supernatant (1.2 mL) was transferred to another tube
and dried under vacuum at 40 °C. The dried residue was reconstituted in 50 μL of acetonitrile
and vortex-mixed for 1 min. After centrifugation at 10,000 rpm for 5 min, the supernatant was
transferred to an autosampler vial, and a 10-μL aliquot of the sample was injected into LC-
MS/MS.
2.8. Method validation
2.8.1. Selectivity—To serve as blanks, plasma and liver samples were obtained from six
different sources and analyzed to assure that they were free of interfering response values, and
the results were compared with those obtained from an aqueous solution of MP at the lower
limit of quantification (LLOQ). The blank liver and plasma samples were also used to test the
matrix effect. This was done by comparing the response values of the extracted blank samples
that were spiked with the drug to those of standards injected directly.
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2.8.2. Extraction recovery—The extraction recovery of MP from plasma and liver was
determined at three concentrations at the lower, middle, and higher parts of the calibration
curves (50, 500, and 2000 ng/mL for plasma and 50, 200, and 800 ng/mL for liver homogenate).
Samples (n = 7) were then subjected to the extraction procedure, and the resultant MP peak
areas were compared to those obtained from direct injection of standard solutions of equivalent
concentrations. The recovery of IS was determined similarly.
2.8.3. Linearity—The linearity of the method was evaluated by calibration curves (n = 5) in
the range of 20–5000 ng/mL and 20–1000 ng/mL for plasma and liver, respectively. Calibration
curves were constructed by plotting peak area ratios of MP to IS against concentration with a
weight of 1/x2.
2.8.4. Accuracy and precision—The intra- and inter-day accuracy and precision were
evaluated by analysis of LLOQ and low, middle, and high quality control (QC) samples with
six determinations per concentration on the same day over three days. The concentration of
each sample was determined using calibration standards prepared on the same day. Accuracy
was expressed as percentage value (% accuracy = [measured concentration/nominal
concentration] × 100%). The precision was estimated as percentage relative standard deviation
(%RSD). For acceptable intra- and inter-day values, accuracy should be within 85–115% and
RSD values should be ≤15% over the calibration range, except at the LLOQ, where accuracy
should be between 80 and 120% and RSD should not exceed 20%.
2.9. Application of the method
2.9.1. In vitro stability of the prodrug during sample preparation and/or storage
—Because of the relatively high in vivo concentrations of dextran prodrugs of MP in plasma
and/or liver, compared with the regenerated MP [7], even a small degradation of the conjugate
in vitro can significantly overestimate the MP concentrations regenerated from the conjugate
in vivo. A previous work on the in vitro stability of dextran-peptide-MP prodrugs showed that
the conjugates are more stable when acetic acid was added to the samples [11]. Therefore, the
in vitro stability of DMP in the plasma and liver samples was studied in the presence and
absence of acid. Blank plasma was spiked with 10% acetic acid solution (4:1, v/v) or water
(control). Similarly, blank liver was homogenized with three volumes of 2% acetic acid
solution or water. A DMP aqueous solution was then added to plasma or liver homogenate to
produce a final concentration of 10 μg/mL (MP equivalent).
To determine the stability of the samples during sample preparation and analysis, a set of spiked
samples were prepared at room temperature and analyzed for their content of released MP
without any storage. The measured values of MP in these samples were then compared with
the free MP impurity in the DMP powder. Further, to determine the stability of the samples
during storage, additional sets of samples were stored at −20 °C or −80 °C, and aliquots were
analyzed at 3, 7, and 14 days after storage. All determinations were conducted in triplicates.
2.9.2. Pharmacokinetic study—All procedures involving animals were conducted in
accordance with the Principles of Laboratory Animal Care (NIH publication #85–23, revised
in 1985), and approved by our Institutional Animal Care and Use Committee. Adult male
Sprague-Dawley rats, weighing between 250 and 300 g, were obtained from Charles River Lab
(Wilmington, MA, USA) and already had a polyethylene cannula inserted into the right jugular
vein. The rats were housed in standard cages and allowed free movement and access to food
and water during the whole experiment.
The dosing solution of the prodrug DMP was dissolved in physiological saline to produce a
concentration of 5 mg/mL (MP equivalent). The dosing solution of the parent drug MP (5 mg/
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mL) was dissolved in a mixture of polyethylene glycol 400: ethanol: saline (6.8: 1.2: 2, v/v)
[15]. A single 5 mg/kg (MP equivalent) dose of either MP or DMP was administered into the
tail veins of rats that were under mild isoflurane anesthesia. At designated time points after
dosing, blood samples (0.3 mL) were taken and centrifuged in heparin-coated microcentrifuge
tubes to obtain plasma. Plasma sample (80 μL) was transferred to a silanized microcentrifuge
tube containing 20 μL of 10% acetic acid solution to prevent DMP hydrolysis in vitro. At the
end of the experiments, animals were euthanized using carbon dioxide, and the liver was
perfused via portal vein using ice-cold saline and blotted dry. All the samples were stored at
−80 °C until analysis within a week.
3. Results and discussion
3.1. Liquid chromatography- mass spectrometry
The mobile phase optimization was accomplished by comparing various solvent systems
composed of mixtures of methanol, acetonitrile, and formic acid. Methanol caused serious ion
suppression with a peak area reduction of approximately 30% compared to acetonitrile. Higher
formic acid concentrations resulted in sharp and narrow peaks. The mobile phase consisting
of a mixture of acetonitrile: 0.5% formic acid aqueous solution (85:15) was found to be suitable
for separation and ionization of MP and IS. The selection of SRM mode and associated
acquisition parameters were evaluated for best response under positive mode by infusing a
standard solution via a syringe pump into the mobile phase. The optimized responses for MP
and IS were obtained. For MP, several possible ion transitions could be considered (m/z
375→357, 375→339, 375→321, 375→253, and 375→161). SRM transitions of m/z 375→161
and 375→357 were selected for MP in plasma and liver, respectively, because they were
specific and abundant ion transitions compared to other ion transitions. SRM of m/z 375→161
was selected for plasma because interferences were found at the SRM of m/z 375→357 in this
matrix.
3.2. Sample preparation, selectivity, and extraction recovery
The pretreatment of the plasma and liver samples proved to be very suitable for a protein-rich
biological matrix. In our previous extraction method for HPLC assay of MP [16], we used a
double-extraction method using hexane and methylene chloride to extract MP from plasma.
Here, a one-step extraction using TBME as the solvent was selected for both plasma and liver
samples. As demonstrated in Figures 2 and 3, analysis of the plasma and liver samples prepared
using extraction with TBME showed no endogenous or extraneous peak interferences with MP
or IS.
The mean extraction recoveries for MP in plasma were 78.3 ± 5.4% at 50 ng/ml, 79.2 ± 5.5%
at 500 ng/mL, and 76.8 ± 5.7% at 2000 ng/ml. The mean recoveries for MP in liver were 80.7
± 8.5%, 76.8 ± 6.0%, and 80.8 ± 6.6% at the concentrations of 50, 200 and 800 ng/mL,
respectively. The mean recoveries for IS from plasma and liver were 86.1 ± 8.8% and 98.1 ±
12.1%, respectively. These results suggested that there was no relevant difference in extraction
recovery at different concentrations of MP in plasma or liver homogenate samples.
Additionally, the liquid-liquid extraction method used here may be less costly than the
previously reported [12] solid-phase extraction of MP.
Chromatographic conditions may cause co-elution of endogenous compounds that are
undetected by the MS-MS but may affect the ionization efficiency. Therefore, the effect of
matrix on the response of the analyte was also evaluated. However, no matrix effect was
detected in our study.
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3.3. Linearity and lower limit of quantification
The calibration model was selected based on the analysis of the data by linear regression with
intercepts and 1/x2 weighting factor. Representative linear equations for MP in plasma and
liver were y = 0.000576 x − 0.00373 in the range of 20–5000 ng/mL and y = 0.00289 x − 0.0183
over the concentration range of 20–1000 ng/mL, respectively. Each standard point in every
calibration curve was back calculated using its own equation. The non-zero standards showed
less than 20% deviation at the 20 ng/mL concentration and less than 15% deviation at all other
concentration levels. The coefficients of determination (r2) for MP in plasma and liver were ≥
0.996. The value of LLOQ was 20 ng/mL for DMP in both plasma and liver, based on 100
μL of plasma or liver homogenate.
3.4. Accuracy and precision
The results of the accuracy and precision are presented in Table 1. The intra- and inter-day
accuracy for MP at 20, 50, 500 and 2000 ng/mL levels in rat plasma fell in the ranges of 85.8–
118% and 89.3–116%, and the intra- and inter-day precision (RSD) were in the ranges of 2.52–
13.1% and 7.10–12.7%, respectively. The intra- and inter-day accuracies for MP at
concentrations of 20, 50, 200 and 800 ng/mL in rat liver were in the ranges of 91.0–99.3% and
92.4–101%, and the intra- and inter-day precisions (RSD) were in the ranges of 2.75–12.6%
and 3.61–15.2%, respectively. Theses data indicate that the repeatability, intermediate
precision, and bias values of the assay are within the acceptance limits of ± 20% at LLOQ and
±15% at other concentration levels.
3.5. Application of the method
3.5.1. In vitro stability of the prodrug during sample preparation and/or storage
—When acetic acid was added to spiked samples and samples were prepared at room
temperature and analyzed without any storage, the MP values were 1.71 ± 0.17% and 1.33 ±
0.05% in plasma or liver samples, respectively. These values are close to the free MP impurity
(0.83 ± 0.09%) in the DMP powder, indicating that regeneration of MP during sample
preparation and analysis at room temperature is negligible in the presence of acetic acid.
However, when acetic acid was not added to the samples, the measured MP levels in the freshly-
prepared plasma and liver samples were 8.35 ± 0.59% and 4.76 ± 0.40%, respectively. The
substantial generation of MP in plasma samples during sample preparation in the absence of
acetic acid is consistent with our previous results, which demonstrated that the half-life of DMP
in rat blood at 37 °C is 4.67 h [11].
Figure 4 depicts the stability data in plasma or liver samples during storage at −20 °C or −80
°C for 14 days. These data were corrected for the MP values measured in samples analyzed
without any storage (time zero). In the absence of acetic acid, significant amounts of MP were
generated during the storage at −20 °C in both plasma (Fig. 4, top) and liver (Fig. 4, bottom).
Reducing the storage temperature to −80 °C improved the storage stability of the conjugate,
although relatively substantial amounts of MP were still generated in vitro in the absence of
acetic acid. Addition of acetic acid to samples before storage almost completely prevented the
in vitro generation of MP from DMP in both plasma and liver at both storage temperatures
(Fig. 4) during the two-week study period. Therefore, the short-term (room temperature sample
preparation) and long-term (storage at −20 or −80 °C) stability data indicate that the addition
of acetic acid not only prevents hydrolysis during the storage (Fig. 4), but is also necessary for
the stability of DMP during sample preparation.
3.5.2. Application to the pharmacokinetic study—The developed assay was applied
to a pharmacokinetic study after intravenous administration of either DMP or MP to rats at a
dose of 5 mg/kg (MP equivalent). The plasma concentration-time profiles of MP following
intravenous administration of DMP or MP are shown in Fig. 5. Additionally, the concentrations
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of regenerated MP in the liver at 8 hr following the administration of DMP were 573 and 707
ng/g in two rats. In contrast, no MP is measurable in the liver 8 hr after the administration of
the parent drug, consistent with the rapid decline of the liver concentration of the drug after
the parent drug administration [7].
4. Conclusion
The pharmacokinetic analysis of MP regenerated from its prodrugs relies on a highly sensitive
assay, capable of determining MP in plasma and liver at a wide concentration range after
systemic administration of the prodrugs. Additionally, the relatively low concentrations of
regenerated MP in the presence of much higher concentrations of the prodrug in vivo requires
validated sample preparation and storage methods, which prevent the in vitro release of MP.
Both of these challenges were met by the method reported here. The LC-MS/MS assay reported
here has demonstrated a rapid separation and specific identification of MP from rat plasma and
liver. Sample clean-up only involves a simple and short solvent extraction step, allowing
sufficient sample-throughput to be applied to pharmacokinetic studies of MP. The results of
the validation show that the method is reproducible and accurate. The analysis requires only
100 μL of plasma, which is advantageous in pharmacokinetic studies in small animals. Thus,
the method proved to be applicable for further pharmacokinetic studies of MP regenerated from
DMP. Additionally, the method may also be applied to the measurements of MP in plasma and
liver samples after the administration of the parent drug.
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Fig. 1.
Chemical structure of (A) dextran-peptide-methylprednisolone succinate prodrug, (B)
methylprednisolone and (C) triamcinolone acetonide (internal standard).
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Fig. 2.
Representative SRM chromatograms (I: m/z 375 →161 for MP; II: m/z 435→415 for internal
standard) for (A) blank plasma containing no internal standard; (B) a spiked plasma containing
MP (200 ng/mL) and triamcinolone acetonide (500 ng/mL); (C) a plasma sample obtained 4
h after intravenous administration of DMP.
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Fig. 3.
Representative SRM chromatograms (I: m/z 375 →357 for MP; II: m/z 435→415 for internal
standard) for (A) blank liver homogenate containing no internal standard; (B) a spiked liver
homogenate containing MP (100 ng/mL) and triamcinolone acetonide (500 ng/mL); (C) a liver
sample obtained 8 h after an intravenous administration of DMP.
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Fig. 4.
The stability of DMP in (top) plasma or (bottom) liver stored with or without acetic acid at
−20 °C or −80 °C. Symbols and error bars represent mean and SD values, respectively (n = 3).
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Fig. 5.
The plasma concentration-time profiles of MP after single intravenous administration of DMP
(closed circles) or MP (open circles) to rats at a dose of 5 mg/kg.
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